Activity description
Treatment approaches for retinal vascular disease are evolving with the introduction of second-generation therapies such as faricimab and high-dose aflibercept (8 mg). What could these changes mean for your clinical practice? Join leading experts as they explore their real-world experiences with these emerging options and dive into key innovations, common challenges, and practical strategies—including OCT monitoring, biomarker utilization, and effective patient engagement—in this dynamic and insightful podcast activity.
When you are finished listening please click here to complete the evaluation and request credit